Cancer prevention and treatment have become a strategic priority for national development and public health. As breast cancer is one of the most common cancers in women, early diagnosis, timely treatment, and evidence-based management are essential. High-frequency ultrasonography is a critical tool for the screening and diagnosis of breast cancer. Artificial intelligence (AI)-assisted ultrasound has shown significant potential in differentiating benign and malignant breast nodules, predicting axillary lymph node metastasis, and evaluating response to neoadjuvant chemotherapy. The experts from the Artificial Intelligence and Remote Ultrasound Group of Ultrasound Medicine Branch of Shanghai Medical Association, the Special Committee on Artificial Intelligence and Remote Ultrasound of Ultrasound Medical Branch of Shanghai Association of Social Medical Institutions, and the Vasculature and Superficial Organ Group of Medical Ultrasound Branch of Chinese Medical Association formed a consensus group. After reviewing the latest domestic and internation literatures and clinical research data, the group reached some consensus on the clinical applications of AI in breast nodule management. This document provides evidence-based recommendations to standardize AI-assisted diagnosis and treatment and serves as a practical reference for clinicians nationwide.